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ABSTRACT   
 
BACKGROUND: Incidence of Chronic Myeloid Leukemia (CML) 
is continuously increasing and expected to reach 100,000 patients 
every year by 2030. Though the discovery of Imatinib Mesylate 
(IM) has brought a paradigm shift in CML treatment, 20% 
patients show resistance to this tyrosine kinase inhibiter (TKI). 
Therefore, it is important to identify markers, which can predict 
the occurrence and prognosis of CML. Clinical Exome 
Sequencing, panel of more than 4800 genes, was performed in 
CML patients to identify prognostic and susceptibility markers in 
CML. 
METHODS: Enrolled CML patients (n=18) were segregated as IM 
responders (n=10) and IM failures (n=8) as per European 
Leukemia Net (ELN), 2013 guidelines. Healthy controls (n=5) 
were also enrolled. DNA from blood of subjects was subjected to 
Next Generation Sequencing. Rare mutations present in one 
patient group and absent in another group were considered as 
prognostic markers, whereas mutations present in more than 50% 
patients were considered as susceptibility markers. 
RESULT: Mutations in genes associated with cancer related 
functions were found in different patient groups. Four variants: 
rs116201358, rs4014596, rs52897880 and rs2274329 in C8A, 
UNC93B1, APOH and CA6 genes, respectively, were present in 
IM responders; whereas rs4945 in MFGE8 was present in IM 
failures. Mutations in HLA-DRB1 (rs17878951), HLA-DRB5 
(rs137863146), RPHN2 (rs193179333), CYP2F1 (rs116958555), 
KCNJ12 (rs76684759) and FUT3 (rs151218854) were present as 
susceptibility markers.  
CONCLUSION: The potential genetic markers discovered in this 
study can help in predicting response to IM as frontline therapy. 
Susceptibility markers may also be used as panel for individuals 
prone to have CML.          
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Incidence of Chronic Myeloid Leukemia in the 
United States is 1.6 per 100,000 of population, 
accounting approximatel for 5,430 cases annually. 
The estimated prevalence in the US is around 
25,000–30,000, which is expected to reach around 
105,000 by the year 2030 (1). Its incidence in 
India is between 0.8–2.2 per 100,000 per annum 
(2). According to  the current estimate, the world 
is expected to have 100,000 newly diagnosed 
CML patients per year, leading this chronic 
disorder into a serious health problem (3). Hence, 
the markers, with potential to detect individuals 
prone to have CML, are very important to control 
rising incidence.  
According to the World Health 
Oraganization guidelines, CML is diagnosed with 
the presence of BCR-ABL gene, which is a 
reciprocal translocation between chromosome 9 
and chromosome 22. Development of BCR-ABL 
inhibitor, Imatinib Mesylate (IM), spectacularly 
changed the prognosis with obstruction of its 
tyrosine kinase activity and impeding its further 
downstream signaling. The drug has high efficacy 
rates: the major molecular response (MMR) of IM 
as first line therapy at 12 months is 22%, which 
increases to 44% at 24 months (4). After 2 years 
of IM therapy, 40% of the patients achieve 
complete molecular response (CMR), which 
further increases to 81% at 10 years of treatment 
(5). Despite this commendable drug discovery, 
approximately 20% of the patients show 
resistance following treatment with this TKI 
therapy (6). European Leukemia Net (ELN) 2013 
recommendations suggest that CML patients on 
first line TKI therapy can be segregated as 
responders or failures, where responders should 
continue with the regimen and failure are advised 
to change the treatment to either more potent TKI 
or dose escalation (7). Though prognostic scores 
(SOKAL and EUTOS) are available for 
estimation of outcomes, they have failed for 
several clinical conclusions (8,9). Therefore, 
genetic markers, with better reliability and 
accuracy, are required for estimation of prognosis 
and planning of personalized medicine in CML. 
In the present study, we performed clinical exome 
sequencing in CML patients to search potential 
prognostic markers for IM response and 
susceptibility markers for CML.     
             
MATERIALS AND METHODS 
 
Subjects: The study was conducted after obtaining 
approval from the Ethics Committee of Sir Ganga 
Ram Hospital, a super specialty tertiary care centre 
in Delhi (India). Informed consent was taken from 
each subject before enrollment in the study. Adult 
patients (>18 years) diagnosed with CML were 
enrolled. Diagnosis of CML was confirmed by 
reverse transcription polymerase chain reaction (RT-
PCR) for BCR-ABL fusion gene and fluorescent in 
situ hybridization (FISH) for translocation (9,22). 
Enrolled patients were classified as responders and 
resistant as per ELN, 2013 criteria. According to 
ELN 2013 criteria, CML patients with ≤10% BCR-
ABL or 35% Ph chromosome are considered as 
responders after 3 months of TKI treatment, whereas 
patients without complete hematological response or 
95% Ph chromosome are considered as resistant. 
After 6 months of treatment, the criteria changes to 
presence of <1% BCR-ABL or 0% Ph chromosome 
for response and for resistance >10% BCR-ABL or 
35% Ph chromosome. Patients harboring <0.1% 
BCR-ABL or are referred as responders and patients 
with >1% BCR-ABL as resistant after 12 months of 
treatment. Beyond 12 months of TKI treatment, loss 
of CHR, CMR or MMR is considered as resistance, 
whereas presence of <1% BCR-ABL is considered 
as optimal response. MMR is defined as presence of 
≤0.1% BCR-ABL for the present study. Patients not 
achieving MMR at 18 months of IM treatment were 
regarded as suboptimal responders, whereas increase 
in BCR-ABL% at any time line compared to 
previous observation was considered as loss of 
molecular response and disease relapse (7). Healthy 
subjects with no known history of malignancy and 
above 18 years of age were also enrolled as controls.           
Peripheral blood sample from both patients and 
controls was obtained in EDTA vials after taking 
informed consent. DNA was extracted (Nucleospin, 
Macheley-Nager, Germany) and was subjected to 
sequencing. 
Clinical exome sequencing  
Next generation sequencing: A targeted panel 
(TruSight One, Illumina, USA) with probes 
covering all coding exons and essential splice 
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sites of >4800 clinically relevant genes was used 
for sequencing the DNA samples using Illumina’s 
TruSight technology (Illumina, USA). The target 
size for this is panel 12 Mb and designed based on 
the information in the Human Gene Mutation 
Database (HGMD), the Online Mendelian 
Inheritance in Man (OMIM) catalogue, 
GeneTests.org, Illumina TuSight sequencing 
panels, etc. 
DNA (50 ng) is taken for library preparation. 
TruSight One library preparation uses transposon 
based shearing of the genomic DNA. A limited 
cycle PCR step allows the incorporation of 
adaptors, platform-specific tags and barcodes to 
prepare the libraries. The tagged and amplified 
sample libraries were analyzed for quality using 
BioAnalyzer (Agilent, USA) and quantified using 
Qubit. And, 500 ng of each library was pooled 
and hybridized to biotinylated probes. The 
hybridized target DNA fragments were pulled 
down using streptavidin beads and two successive 
enrichment steps were performed to optimize the 
regions of interest. Target libraries were amplified 
using loaded for sequencing on the MiSeq or 
HiSeq (Illumina, USA) to obtain ~3 GB per 
sample.  
Sequence analysis: The trimmed FASTQ files 
were generated using MiSeq Reporter from 
Illumina for MiSeq data and Casava software for 
HiSeq data. The reads were aligned against the 
whole genome build hg19 using STRAND® NGS 
V2.1.6 (Strand LifeSciences Pvt. Ltd., 
Bangalore). Five base pairs from the 3' end were 
trimmed, as 3' end were bases with quality below 
10. Reads which had lengths less than 25 bp after 
trimming were not considered for alignment. A 
maximum of 5 matches of alignment score at least 
90% were computed. Reads that failed QC 
(quality control), reads with average quality less 
than 20, reads with ambguous characters were all 
filtered out. The STRAND® NGS variant caller 
was used to detect variants at locations in the 
target regions covered by a minimum of 10 reads 
with at least 2 variant reads. Variants with a 
decibel score of at least 50 were reported.  
Interpretation: Interpretation of the variant data 
was done using the StrandOmics software, V1.9. 
The variant annotation engine includes different 
algorithms to identify variant impact on gene 
using public content (HGMD, ClinVar, OMIM, 
HPO, links to dbSNP, 1000 Genomes, Exome 
Variant Server) and proprietary content (curated 
variant records). 
Statistical analysis: Statistical analyses were 
performed using SPSS for Windows 16 (SPSS, 
Chicago IL, USA). Non-parametric data is 
presented as median with standard deviation (SD). 
Statistical significance of differences of 
quantitative data was determined using Mann-
Whitney U test. P-value of less than 0.05 was 
considered to be significant.     
Ethics statement: The study and informed 
consent forms were reviewed and approved by the 
Ethics Committee of Sir Ganga Ram Hospital, 
Delhi, India (EC No.: EC/11/12/439). All 
procedures performed in the this study were in 
accordance with the ethical standards of the 
institutional research committee and with the 




Subjects: Eighteen patients and five healthy 
controls were enrolled in the study. Mean (SD) 
age of patients was 42.11 (12.76) years, whereas 
that of controls was 38.40 (12.76) years (p = 
0.570). All the patients were in chronic phase at 
the time of diagnosis. The IM responder group 
had 10 patients (55.55%), while 8 patients 
(44.45%) were in IM failure group. Patient no.4 
and patient no.5 were included in responder group 
despite having >1% of BCR-ABL as the patients 
were responding well to IM therapy. Reduction in 
BCR-ABL percentage (compared to time of 
diagnosis) from 9.8% to 1.3% in patient no.4 and 
from 8.6% to 1% in patient no.5 was observed in 
span of 4 months and 5.5 months respectively. 
The mean (SD) age of the responder group was 
35.1 (6.74) years, whereas failure was 
50.88(13.36) years (p = 0.05).  
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Genetic markers: Our main objective was to detect prognostic and 
susceptibility markers. The criterion for genetic variants to be considered as 
marker was presence in at least 50% patients of one group and absence in all 
patients of the opposite group, whereas mutations present in more than 50% 
(≥9) of CML patients were considered as susceptibility markers. Only rare 
mutations, which were not present in healthy population of Asia, Europe and 
Africa as per HapMap project, were considered. The shortlisted mutations 
were annotated manually with GeneCards and Kegg pathways for their 
functions (Table 3). Important genetic information about discovered mutations 
is given in Table 1. 
 
 
Table 1: Genetic information of potential markers discovered in CML patients 
 
 
€Chromosomal Position = Chromosome no.; nucleotide position,   ▲CpG = Cytosine phosphate Guanine  
 
Mutation Gene Allele Accession No. Chromosomal Position€  Codon Amino Acid change CpG islands▲ 
Markers for IM Responder 
c.107C>A (rs116201358) C8A A/C NM_000562.2 1; 57333311 GCA-GAA p.36Ala>Glu None 
c.1494G>A (rs4014596) UNC93B1 C/T NM_030930.2 11; 67759316 GTG-ATG p.499Val>Met 67758155-67759445 
c.422T>C (rs52797880) APOH A/G NM_000042.2 17; 64216854 ATC-ACC p.141Ile>Thr None 
c.209G>C (rs2274329) CA6 C/G NM_001215.3 1; 9009451 GGC-GCC p.70Gly>Ala None 
Marker for IM Failures 
c.7C>A (rs4945) MFGE8 G/T NM_001114614.1 15; 89456544 CGC-AGC p.3Arg>Ser 89456225-89456830 
CML Susceptibility Marker 
c.181T>C (rs137863146) HLA-DRB5 G/G NM_002125.3 6; 32489871 TAT-CAT p.61Tyr>His 32489743-32490128 
c.200T>C (rs17878951) HLA-DRB1 A/G NM_002124.3 6; 32552056 GTG-GCG p.67Val>Ala 32551852-32552331 
c.1070A>T (rs193179333) RHPN2 A/T NM_033103.4 19; 33493188 CAC-CTC p.357His>Leu None 
c.798G>C (rs117958555) CYP2F1 C/G NM_000774.3 19; 41628014 CAG-CAC p.266Gln>His None 
c.785T>G (rs76684759) KCNJ12 G/T NM_021012.4 17; 21319439 ATC-AGC p.262Ile>Ser 21318651-21320041 
c.1007A>C (rs151218854) FUT3 G/T NM_000149.3 19; 5843844 GAT-GCT p.336Asp>Ala None 
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Clinical exome analysis: Data was uploaded to 
SeatttleSeq Annotation 141  
(http://snp.gs.washington.edu/SeattleSeqAnnotati
on141) for annotation. Analysis of patients and 
controls was done separately. All the variants 
present in the control group were aligned in one 
table and all variants of patients group were 
aligned in another table. In total, 97,462 variants 
in patients and 65,546 variants in controls were 
found. After filtration of common variants, 45,950 
variants were selected exclusively in the patient 
group. The distribution of genetic variants in the 
patient group included 30,525 intronic, 2,837 
variants were in untranslated regions (3’UTR = 
1,737 and 5’ UTR = 1,100), 5,132 variations were 
synonymous and 7,494 variants were non-
synonymous. Non-synonymous mutations were 
further segregated as 6,524 missense mutations, 
766 frame-shift and 166 stop gained/stop lost 
mutations (Figure 1). We targeted only missense 
mutations, as these mutations play a central role 
in altering phenotype of the gene at protein level. 
 
Variant analysis of significant genes: Total 2, 
033 missense variants were common in at least 2 
patients, and only 273 variants were left after 
considering the variants present in more than 25% 
(≥5) patients. These variants were further 
analyzed for molecular pathway and functional 
correlation with CML. All the mutations observed 
were subjected to Kyoto Encyclopedia for Genes 
and Genomics (Kegg) pathways and GeneCards 
to identify the cellular pathway and functions 
associated with the mutated genes. We focused on 
the genes which were most frequently mutated in 
this group.  
 
Figure 1: Work flow of clinical exome data interpretation to define potential prognostic and susceptibility markers 
in CML cohort. 
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Prognostic marker variants: We discovered rs116201358 (c.107C>A) in 
C8A, rs4014596 (c.149G>A) in UNC93B1, rs52797880 (c.422T>C) in APOH 
and rs2274329 (c.209G>C) in CA6 as markers for good response as mutations 
were present in responding patients only.  
Amongst these mutations, rs116201358 (c.107C>A) and rs2274329 
(c.209G>C) are expected to be most damaging (Polyphan score: 0.994 and 1 
respectively), while rs4014596 (c.149G>A) was moderately damaging (Table 
2).  
In the treatment failure group, rs4945 (c.7C>A) in MFGE8 was 
discovered. The mutation lies in conserved region and expected to be 
moderately damaging (SIFT: 0.00, Polyphan score: 0.65) (Table 2). 
HLA-DRB1 and HYDIN had 5 variants each, whereas HLA-A had 4 
variants (Supplemantory Table 2). These genes demonstrated maximum 
number of variants among all the genes. Apart from these candidate genes, 
CPZ, NSD1, PER3, SDHA and TAS2R43 had 3 mutations each 
(Supplemantory Table 2). All the remaining genes had either 1 or 2 variation.  
 
 
Table 2: Damaging potential of candidate variants related to CML prognosis and susceptibility. 
 
▲MAF = Minor allele frequency of variant according to dbsnp (NCBI), €SIFT = Sorting Intolerant From Tolerant, αGERP = Genomic Evolutionary Rate Profiling, µn = total number of patients in 
respective  
 
Mutation Gene Allele MAF▲ (dbsnp) Mutation scoring Patients (nµ) 
 SIFT€ Polyphan Grantham GERPα Responders (n=10) Failures (n=8) Total (n=18) 
Markers for IM Responder 
c.107C>A (rs116201358) C8A A/C 0.021 0.00 0.994 107 5.09 5 0 5 
c.1494G>A (rs4014596) UNC93B1 C/T 0.048 0.00 0.744 21 2.8 5 0 5 
c.422T>C (rs52797880) APOH A/G 0.066 0.00 0 89 3.37 5 0 5 
c.209G>C (rs2274329) CA6 C/G 0.0004 0.00 1 60 3.39 5 0 5 
Marker for IM Failures 
c.7C>A (rs4945) MFGE8 G/T 0.435 0.00 0.065 110 -0.479 0 4 4 
CML Susceptibility Marker 
c.181T>C (rs137863146) HLA-DRB5 G/G 0.011 0.00 0.021 83 1.02 7 5 12 
c.200T>C (rs17878951) HLA-DRB1 A/G NA 0.00 0 64 -0.433 9 6 15 
c.1070A>T (rs193179333) RHPN2 A/T 0.031 0.00 0.989 99 4.61 6 4 10 
c.798G>C (rs117958555) CYP2F1 C/G 0.008 0.00 0.994 24 -4.65 7 2 9 
c.785T>G (rs76684759) KCNJ12 G/T 0.197 0.00 0.999 142 5.43 7 5 12 
c.1007A>C (rs151218854) FUT3 G/T 0.002 0.00 0 126 -4.57 6 5 11 
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Susceptibility marker: HLA family genes HLA-
DRB1 had rs17878951 (c.200T>C) and HLA-
DRB5 had rs137863146. Other mutations 
observed in our cohort as CML susceptibility 
markers were rs193179333 in RHPN2, 
rs117958555 in CYP2F1, rs76684759 in KCNJ12 
and rs151218854 in FUT3. Among these 
mutations, rs193179333, rs117958555 and 
rs76684759 were most deleterious as per SIFT, 
Polyphan, Grantham and GERP scoring (Table 2). 
 
Supplementary Table 2: Summary of most mutated genes (in ≥5 CML patients) revealing effected pathway and 







Associated Pathways/ Functions  
HLA-
DRB1 
rs17885382 6 hsa04514:Cell Adhesion Molecules(CAMs); hsa04612:Antigen 
Processing and Presentation; hsa04640:Hematopoietic Cell Lineage; 
hsa04672:Intestinal Immune Network For IgA Production; 
hsa04940:Type I Diabetes Mellitus; hsa05140:Leishmaniasis; 
hsa05310:Asthma; hsa05320:AutoimmuneThyroid Disease; 
hsa05322:Systemic Lupus Erythematosus; hsa05330:Allograft 
Rejection; hsa05332:Graft-versus-host Disease; hsa05416:Viral 





HYDIN rs147394921 8 Involved in cilia motility. Mutations in this gene cause of autosomal 




HLA-A rs1059455 6 hsa04144:Endocytosis; hsa04514:Cell Adhesion Molecules (CAMs); 
hsa04612:Antigen Processing And Presentation; hsa04650:Natural 
Killer Cell Mediated Cytotoxicity; hsa04940:Type I Diabetes 
Mellitus; hsa05320:Autoimmune Thyroid Disease; 
hsa05330:Allograft Rejection; hsa05332: Graft-versus-host Disease; 




CPZ rs79736750 6 Encodes Carboxypeptidase Z,. has carboxypeptidase activity towards 
substrates with basic C-terminal residues (GeneCards).  rs35993494 6 
rs34964084 5 
NSD1 rs35848863 7 hsa00310:Lysine Degradation (Kegg Pathways) 
 rs34165241 7 
78247455 5 
PER3 rs10462020 7 hsa04710:Circadian Rhythm-Mammal (Kegg Pathways) 
 rs10462021 7 
rs2640909 10 
SDHA rs1042052 5 hsa00020:Citrate Cycle (TCACycle); hsa00190:Oxidative 
Phosphorylation; hsa01100:Metabolic Pathways; 
hsa05010:Alzheimer's Disease; hsa05012: Parkinson's Disease; 
hsa05016: Huntington's Disease (Kegg Pathways) 
rs10426960 6 
rs10426962 6 
TAS2R43 rs111846092 10 hsa04742:Taste Transduction (Kegg Pathways) 
 rs200533679 7 
rs201618803 9 
▲rsID = rsiD provided in DBSNP (NCBI), €n = total number of patients enrolled 
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Table 3: Functional annotation of genes having potential markers using Kegg pathways and Gene Cards. 
 
 
Gene   Patients▲ Associated Pathways/Functions  
Genes of Responder Markers 
C8A P2, P3, P4, P5, 
P8 
hsa04610:Complement And Coagulation Cascades; hsa05020:Prion 
Diseases; hsa05322:Systemic Lupus Erythematosus (Kegg Pathways) 
UNC93B1 P2, P3, P4, P5, 
P7 
Regulates toll-like receptor Signaling. Protein deficiency associated with 
herpes simplex encephalitis. (GeneCard)   
APOH P4, P5, P6, P8, 
P10  
Associated with lipoprotein metabolism, coagulation, and the production of 
antiphospholipid autoantibodies. (GeneCard) 
CA6 P3, P4, P5, P7, 10 hsa00910:Nitrogen Metabolism. (Kegg Pathways) 
Gene of Failure Marker 
MFGE8 P11, P13, P16, 
P18 
Encodes Lectadherin, involved in phagocytosis of apoptotic cells. Implicated 
in healing, autoimmune disease and cancer. (GeneCard) 
Genes of Susceptibility Markers 
HLA-
DRB5 
hsa04514: Cell Adhesion Molecules (CAMs); hsa04612:Antigen Processing And Presentation; 
hsa04640:Hematopoietic Cell Lineage; hsa04672:Intestinal Immune Network For IgA 
Production; hsa04940:Type I Diabetes Mellitus; hsa05140:Leishmaniasis; hsa05310:Asthma; 
hsa05320:Autoimmune Thyroid Disease; hsa05322:Systemic Lupus Erythematosus; 




hsa04514:CellAdhesionMolecules(CAMs); hsa04612:Antigen Processing And Presentation; 
hsa04640:Hematopoietic Cell Lineage; hsa04672:Intestinal Immune Network For IgA 
Production; hsa04940:Type I Diabetes Mellitus; hsa05140:Leishmaniasis; hsa05310:Asthma; 
hsa05320:Autoimmune Thyroid Disease; hsa05322:Systemic Lupus Erythematosus; 
hsa05330:Allograft Rejection; hsa05332:Graft-versus-host Disease; hsa05416:Viral Myocarditis 
(Kegg Pathways) 
RHPN2 Encodes Rho-GTPase binding protein. Involved in actin cytoskeleton. (GeneCard).  
CYP2F1 hsa00980:Metabolism of Xenobiotics By Cytochrome P450 (Kegg Pathways) 
KCNJ12 Encodes K+ channels. (GeneCard) 
FUT3 hsa00601:Glycosphingolipid Biosynthesis Lacto And Neolacto Series; hsa01100:Metabolic 
Pathways (Kegg Pathways) 




The discovery of Imatinib Mesylate in drastically 
changed the scenario of CML treatment. Despite 
the paradigm shift in prognosis, around 20% of 
patients fail to achieve expected remission (6). 
Increasing incidence of CML will soon convert it 
into a serious medical problem. Therefore, 
discovery of more prognostic markers which will 
help in proper outcome estimation and planning 
for personalized CML treatment is required. 
Susceptibility markers are also needed to control 
increasing incidence of CML. The susceptibility 
markers identified have been reported for the first 
time in the present study. Therefore, these 
findings are required to be validated in larger 
cohort of CML patients. Once validated, these 
markers can be tested in high risk population, 
which is more prone to develop CML (10,11). In 
search of the potential prognostic and 
susceptibility markers, we performed NGS in 18 
CML patients, classified as responders and 
failures. In the responder group, recommended 
time line for analysis (3 months and 6 months) 
was customized in case of 2 patients to detect 
BCR-ABL% for research purpose. Change in the 
time line of BCR-ABL analysis of patients for 
research purpose was one of the limitations of the 
study.  
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The key objective of the study was to find 
missense variants, capable of predicting the 
outcome of patients treated with Imatinib 
Mesylate as frontline therapy and potential 
markers to detect healthy individuals prone to 
have CML. As per the criterion for prognostic 
markers, we demonstrated mutations in 5 genes as 
markers. Out of these 5 variations observed, 
mutation in MFG-E8 was in the failure group, 
whereas 4 mutations, discovered in the 
responders, were in genes C8A, UNC93B1, 
APOH and CA6.  
Prognostic markers: MFG-E8 (Milk Fat 
Globule–Epidermal growth factor-8), is primarily 
responsible for production of membrane 
glycoprotein lactadherin, which promotes 
phagocytosis of apoptotic cells. In melanoma 
cells, MEG-E8 promotes progression by 
triggering epithelial to mesenchymal transition, 
stimulated invasion and immune suppression, 
whereas the high expression is linked with disease 
progression in oral cancer, breast cancer, prostate 
cancer and colon cancer (12-16). As this gene was 
found to be involved in the progression of many 
cancers, rs4945, discovered in our study was also 
expected to be associated with IM treatment 
failure in CML.  
Complement component 8-alpha (C8A), 
encodes alpha subunit of C8. C8A participates in 
the formation of membrane attack complex 
(MAC). Elevated RNA levels of C8A gene were 
associated with better prognosis of Hepatocellular 
carcinoma (17) and in breast cancer patients, 
treated with trastuzumab (18). We found a 
deleterious mutation, rs116201358 in the 
responders, which seems to be related with better 
treatment outcome similar to elevated expression 
in earlier studies. 
UNC93B1 (Unc-93 homolog B1) is involved 
in regulation of toll like receptor signaling. The 
encoded protein traffics nucleotide sensing 
receptors to endolysosomes from endoplasmic 
receptor. It is an IFN1 signature gene, induced by 
chemotherapy cyclophosphoamide. IFN1 has 
recently been found involved in inducing anti-
tumor immunity (19). Impaired UNC93B1 
dependent immunity is also associated herpes 
simples virus 1 encephalitis (HSE) pathogenesis 
in children (20). We observed that the presence of 
mutation rs4014596 in the majority of the 
responder patients associates it with better 
prognosis, due to potential role in anti-tumor 
immunity.  
APOH (Apolipoprotein H) is linked with 
several pathways including lipoprotein 
metabolism, coagulation and the production of 
antiphospholipid antibodies. Its elevated serum 
levels were found to be associated with incidence 
of colorectal cancer (21), better prognosis in 
Estrogen Receptor negative (ER-ve) breast cancer 
(22) and acute myeloid leukemia (23). We 
observed mutation rs52797880 in IM the 
responding cohort, which corroborated with the 
previous findings correlating elevated serum 
levels with better prognosis in breast cancer and 
AML.  
Carbonic Anhydrase 6 (CA6) is a protein 
involved in reversible hydration of carbon-di-
oxide in saliva. Strong expression of this gene is 
associated with serous adenocarcinomas of ovary 
and endometrium (24,25), in carcinomas of 
breast, pancreas, urothelium and cancers of renal 
and pulmonary origin (26). In our cohort, 60% of 
the responding patients had mutation rs2274329, 
which makes it a potential candidate as marker for 
better prognosis 
Co-occurance of different genetic variants in 
an individual or a group of patients is considered 
as haplotype marker (27). In this study, we 
observed the co-existence of rs116201358 with 
rs4014596 and rs4014596 with rs2274329 in 4 
and 3 IM responding patients respectively (Table 
3). This observation suggests that coexistence of 
mentioned variants can be a potential haplotypes 
for good prognosis in CML patients.    
Susceptibility markers: In our search for CML 
susceptibility markers, we observed rs17878951 
and rs137863146 in HLA-DRB1 (Major 
Histocompatibility Complex Class II, DR Beta1) 
and HLA-DRB5 in our cohort. Both of the genes 
are participants of Interferon-gamma and CXCR4 
signaling and play a key role in antigen 
presentation. Variants of HLA-DRB1 were found 
to be associated with incidence of CML in 
different populations throughout the world (28-
32), and overexpression of HLA-DRB5 is a 
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potential susceptibility marker of Lung cancer 
(33), whereas the genetic variants are markers for 
CLL (34) and breast cancer (35). Another variant 
(rs193179333) of RHPN2 (Rhophilin Rho 
GTPase Binding Protein 2) gene, which codes for  
Ras Homologous (Rho)-GTPase binding protein, 
was observed in 10 CML patients of our cohort. 
The RHPN2 binds to GDP and GTP bound RhoA 
and RhoB, involved in organization of actin 
cytoskeleton. Mutations of RHNP2 are linked 
with suspicion of colorectal cancer incidence (36), 
prognosis of lung adenocarcinoma and malignant 
glioma (37,38). The polymorphism of CYP2F1 
(Cytochrome P450 family 2 subfamily F member 
1) gene is linked to lung cancer in different 
ethnicities (39), whereas differential expression 
are associated with prognosis of ovarian and 
breast cancer (40-42). In this study, rs117958555 
was found in the majority of CML patients, which 
hints at being a susceptibility marker. In normal 
circumstances, it is involved in drug metabolism, 
hence genetic change in the gene can be possibly 
related to pathogenesis of CML.  However, FUT3 
(Fucosyltransferase 3) is involved in 
embryogenesis, tissue differentiation,  tumor 
metastasiss and inflammation. Incidences of 
gastro-intestinal and breast cancer are linked to 
FUT3 genetic variations (43,44). Similarly, we 
also discovered rs151218854 in FUT3 related to 
incidence of CML. We also observed another 
mutation rs76684759 in KCNJ12 (Potassium 
Voltage-Gated Channel Subfamily J Member 12), 
Normal KCNJ12 gene is involved in  cardiac 
inward rectifier current (IK1). Its association with 
any type of cancer is not reported to the best of 
our knowledge, but we observed rs76684759 in 
more than 70% of our patients. The mutation is 
present in conserved region (SIFT Score: 0) and 
highly damaging (Polyphan : 0.999).  
In conclusion, we discovered 11 missense 
mutations, as potential prognostic and 
susceptibility markers. Variants in C8A, 
UNC93B1, APOH and C6A genes were found in 
IM responders whereas variant of MFGE8 was 
present in IM failures. Susceptibility markers 
were discovered in HLA-DRB1, HLA-DRB5, 
RHPN2, CYP2F1, KCNJ12 and FUT3. All the 
genes were associated with cancer. The study is a 
step forward to discovering reliable markers for 
selecting individuals prone to CML and estimate 
the outcome of treatment. The findings of the 
study can be useful in individualizing cancer 
treatment after validation of discovered mutations 
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